Invesco Ltd. Arbutus Biopharma Corp Transaction History

Invesco Ltd.

$453 Billion
Q1 2024

A detailed history of Invesco Ltd. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Invesco Ltd. holds 59,538 shares of ABUS stock, worth $188,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,538

Previous 56,673 5.06%

Holding current value

$188,140

Previous $141,000 8.51%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.26 - $2.92 $6,474 - $8,365	2,865 Added 5.06%	59,538 $153,000
Q4 2023 Feb 12, 2024	BUY	$1.69 - $2.54 $98 - $147	58 Added 0.1%	56,673 $141,000
Q3 2023 Nov 13, 2023	BUY	$1.9 - $2.27 $5,842 - $6,980	3,075 Added 5.74%	56,615 $114,000
Q2 2023 Aug 11, 2023	BUY	$2.24 - $3.06 $14,750 - $20,150	6,585 Added 14.02%	53,540 $123,000
Q1 2023 May 12, 2023	BUY	$2.23 - $3.1 $3,559 - $4,947	1,596 Added 3.52%	46,955 $142,000

Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $14,122 - $21,072	7,394 Added 19.48%	45,359 $105,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $5,499 - $8,424	2,925 Added 8.35%	37,965 $72,000
Q2 2022 Aug 15, 2022	BUY	$1.98 - $3.17 $16,121 - $25,810	8,142 Added 30.27%	35,040 $95,000
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $3,661 - $6,021	1,513 Added 5.96%	26,898 $80,000
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $11,802 - $17,494	-3,795 Reduced 13.01%	25,385 $99,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $10,584 - $18,452	3,994 Added 15.86%	29,180 $126,000
Q2 2021 Aug 17, 2021	BUY	$2.5 - $3.51 $62,965 - $88,402	25,186 New	25,186 $76,000

Others Institutions Holding ABUS

# of Institutions

130

Shares Held

82.2M

Call Options Held

4.82M

Put Options Held

546K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $474M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account